eyenovia-logo 3

News Release

Printer Friendly Version View printer-friendly version
<< Back
Eyenovia to Present at the 20th Annual H.C. Wainwright Global Investment Conference

NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer, is scheduled to present at the 20th Annual H.C. Wainwright Global Investment Conference taking place on September 4-6, 2018 at The St. Regis New York.

Details of the presentation are below:

Event: 20th Annual H.C. Wainwright Global Investment Conference
Date: Thursday, September 6, 2018
Time: 4:15pm ET
Location: Fontainebleau Room (Floor 2)

A live webcast of the presentation may be accessed on the Company's website at http://eyenoviabio.com. The webcast will be archived for 90 days following the live presentation on the Company's website.

About Eyenovia
Eyenovia, Inc. (NASDAQ: EYEN) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, glaucoma and other eye diseases.

Company Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
[email protected]

Investor Contact:
Tram Bui / Alexander Lobo
The Ruth Group
Phone: 646-536-7035/7037
E-mail: [email protected] / [email protected]

Media Contact:
The Ruth Group
Kirsten Thomas
508-280-6592
[email protected]

Primary Logo

Eyenovia, Inc.

Contact us for more information

Contact us today to learn more about how our microdosing technology is poised to transform
the standard of care in ophthalmic therapeutic delivery.

New York    501 Fifth Avenue, Suite 1404 New York NY 10017     +1 (917) 289-1117

[email protected]